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Purpose: Numerous studies, including those using animal models of myopia development and human clinical trials, have
shown that the non-selective muscarinic antagonist atropine is effective in preventing the axial elongation that leads to
myopia development. Among all of the muscarinic acetylcholine receptors (mAChRs), mAChR 1 (M1) was the most
effective in preventing myopic eye change. Our specific aim in this study was to examine the association between high
myopia and polymorphisms within the muscarinic acetylcholine receptors 1 gene (CHRM1).
Methods: The participants comprised of a high myopia group (n=194; age range, 17–24 years) having a myopic spherical
equivalent greater than 6.5 diopters (D) and a control group (n=109; age range, 17–25 years) having a myopic spherical
equivalent less than 0.5 D. Genotyping was performed using an assay-on-demand allelic discrimination assay. Polymerase
chain reaction (PCR) was performed using 96 well plates on a thermal cycler. The polymorphisms detected were S1
(CHRM1 rs11823728), S2 (CHRM1 rs544978), S3 (CHRM1 rs2186410), and S4 (CHRM1 rs542269).
Results: There was a significant difference in the distribution of S2 and S4 between the high myopia and control groups
(p=2.40×10−6 and 2.38×10-8, respectively). The odds ratios of AA genotype of S2 and GG genotype of S4 were both 0.08
(95% confidence interval [CI]: 0.02–0.29 and 0.02–0.36, respectively). Logistic regression test revealed S1, S2, and S4
CHRM1 as all being significant in the development of high myopia. Moreover, the distributions of haplotype 4 (Ht4; C/
A/A/A) differed significantly between the two groups (p=3.4×10−5, odds ratio: 0.1, 95% CI: 0.03–0.34).
Conclusions: Our results suggest that the S2 and S4 polymorphisms of CHRM1 are associated with susceptibility for
developing high myopia. S1, S2, and S4 CHRM1 had a co-operative association with high myopia.
Clinically  significant  refractive  errors  are  the  most
common type of visual disorders. Myopia affects more than
half of the young adult population in the world [1-3]. In Asian
countries, the prevalence of myopia has approached epidemic
proportions  [4].  A  range  of  animal  models  of  myopia
development  have  demonstrated  that  the  non-selective
muscarinic acetylcholine antagonist, atropine, is effective in
preventing  the  axial  elongation  that  leads  to  myopia
development [5-9]. Human clinical trials have also shown an
effectiveness of daily atropine administration in reducing the
progression  of  myopia.  The  muscarinic  acetylcholine
receptors (mAChRs) are a group of neurotransmitter proteins
belonging  to  the  seven  transmembrane  superfamily  of
receptors.  Five  distinct  receptor  genes  (CHRM1-CHRM5)
have  been  cloned,  each  encoding  a  muscarinic  receptor
protein  1–5  (M1-M5)  with  specific  pharmacological
Correspondence  to:  Fuu-Jen  Tsai,  M.D.,  Ph.D.,  Department  of
Medical Genetics, China Medical University Hospital, No. 2 Yuh
Der  Road,  Taichung  404,  Taiwan;  Phone:  886-4-22052121  ext.
2041; FAX: 886-4-22033295; email: d0704@mail.cmuh.org.tw
properties [10-12]. In the study of guinea pigs, M1 and M4
subtypes  were  found  to  be  significantly  increased  in  the
posterior sclera of form-deprived myopic eyes. Studies of the
individual  muscarinic  antagonists  had  revealed  that  M1
selective pirenzepine and M2/M4 selective himbacine were
effective in inhibiting the development of myopia [8,13,14].
Pirenzepine,  an  M1  selective  antagonist,  is  effective  in
preventing the progression of myopia in a dose-dependent
manner  in  both  mammalian  and  avian  models  [8,13,15].
According to the previous studies, we understood that among
all mAChRs, M1, M2, and M4 might have the most important
roles in the “stop” signal of myopic progression. In vitro
studies  had  found  that  mAChR  antagonists  inhibit
proliferation and matrix synthesis of the cartilaginous sclera.
There was a rank order of the selective antagonists in the
function  of  reducing  incorporation  of  sulfate  into
glycosaminoglycans (GAGs) by chondrocytes. The rank of
potency was M1 (pirenzepine-telenzepine) > Ml and M3 (4-
diphenylacetoxy-N-methylpiperidine  methiodide  [4-
DAMP]) > M2 (gallamine). The ranking suggests that the Ml
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1774subtype is the most dominant type to regulate scleral growth
[16].
Many studies have suggested that myopia is a complex
disease  with  multiple  causes  including  the  interaction  of
multiple genes with environmental stimuli [17]. Therefore, to
understand myopia, it is necessary to take both genes and
environment into account [17]. There is evidence supporting
the premise that myopia and refractive errors are in large part
genetically determined. This comes from twin studies and
from studies of refractive errors in parents and their children
[18,19]. A well conducted study has shown that refractive
errors were much more strongly correlated in monozygotic
twins than in dizygotic twins [19]. In the present study, we
investigated the association of genetic polymorphisms in M1
and  high  myopia.  The  gene  encoding  the  M1  receptor,
muscarinic  acetylcholine  receptors  1  gene  (CHRM1),  is
localized  to  11q13.  Four  genetic  polymorphisms  were
selected  using  HapMap,  genotypes  were  analyzed  within
Haploview  and  tag  SNPs  were  selected  using  the  Tagger
function. The polymorphisms were rs11823728 in the 3′UTR
and rs544978, rs2186410, and rs542269 in the intron.
METHODS
Patients: Between February to November 2004, we measured
the refractive error in 3,000 volunteers. All of the participants
were  medical  students,  unrelated,  and  Taiwan-born  Han
Chinese. The enrolled participants in this study were aged 16–
25 years (mean age of 18±3.2 years), and the male to female
ratio was 1.8:1.0. All participants had a visual acuity with
distance  correction  of  0.2  logMAR  (20/32)  or  better.
Refractive error was measured in diopters (D) and determined
by the mean spherical equivalent (SE) of the two eyes of each
individual after administering one drop of cycloplegic drug
(1% mydriacyl; Alcon, Berlin, Germany). Individuals with
myopia  greater  than  or  equal  to  6.5  D  (both  eyes)  were
included in the high myopia group, and those with myopia less
than 0.5 D and hyperopia less than 1.0 D (both eyes) were
included in the control group. Patients with astigmatism with
a refractive error more negative than -0.75 D were excluded
from the study since it would alter the results of SE. The study
was reviewed by the ethics committee of the China Medical
University Hospital (Taichung, Taiwan) and performed in
accordance with the tenets of the Declaration of Helsinki for
research involving human subjects. Informed consent was
obtained from all participants. A comprehensive ophthalmic
examination and blood collection were performed. None of
the  participants  had  ocular  disease  or  insult  such  as
retinopathy,  prematurity,  neonatal  problems,  a  history  of
genetic disease, and connective tissue disorders associated
with myopia such as Strickler or Marfan syndromes. Clinical
examinations  included  visual  acuity,  refraction  error,  slit-
lamp examination, ocular movements, intraocular pressure,
and fundoscopy. Patients with organic eye disease, a history
or  evidence  of  intraocular  surgery,  history  of  cataract,
glaucoma, retinal disorders, or laser treatment were excluded.
As with all data collection procedures, auto-refraction (Auto-
refractor/auto-keratometer  [ARK  700A;  Nikon,  Tokyo,
Japan])  was  conducted  on  both  eyes  by  experienced
optometrists  who  were  trained  and  certified  on  the  study
protocols. Refractive data, sphere (s), negative cylinder ©, and
axis  measurements  were  analyzed  by  calculating  SEM
refractive error.
Genotype determinations: To select the most representative
SNPs to capture the majority genetic variation, SNP genotype
information was downloaded in December, 2007 from the
HapMap (haplotype map of the human genome project) HCB
(Han Chinese in Beijing, China) or JPN (Japanese) population
from an extended 30Kb region of Chromosome 11. HapMap
genotypes were analyzed within Haploview and Tag SNPs
were selected using the Tagger function. Four tag SNPs were
selected  for  each  gene  with  r2≥0.80  to  capture  80%  of
genotype information in the region. The average tag SNP was
with r2=0.901. Genotyping was achieved using an assay-on-
demand allelic discrimination assay and a detection system
according  to  the  manufacturer’s  instructions  (Applied
Biosystems  Co,  Foster  City,  CA).  The  polymerase  chain
reaction (PCR) reaction contained 10 ng of genomic DNA,
10 μl TaqMan master mix, and 0.125 μl of 40X assay mix.
PCR was performed using 96 well plates on a thermal cycler
(ABI 9700; Applied Biosystems). Reaction conditions were
50 °C for 2 min and 95 °C for 10 min followed by 40 cycles
of 95 °C for 15 s and 60 °C for 1 min. Four polymorphisms
met the criteria and were selected in this study. They were S1
(CHRM1 rs11823728), S2 (CHRM1 rs544978), S3 (CHRM1
rs2186410), and S4 (CHRM1, rs542269). Haplotypes were
inferred from unphased genotype data using the Bayesian
statistical method available in the software program, Phase
2.1. All five SNPs were analyzed with the Phase 2.1 software
[20].
Statistical  analysis:  Genotypes  were  obtained  by  direct
counting with subsequent calculation of allele frequencies.
Data were analyzed using the χ2 test or Fisher's exact test, and
p values were calculated using the Minitab program (Minitab
Inc., San Jose,CA). A p value less than 0.05 was considered
statistically  significant.  The  odds  ratios  (OR)  and  the
corresponding 95% confidence intervals (CI) were calculated
for associations concerning allele and genotype. Bonferroni
corrections for multiple comparisons were performed [21].
All of the detected SNPs were assessed for Hardy–Weinberg
equilibrium (HWE) using the χ2 test [22]. Stepwise logistic
regression was used to determine if any one accounted for the
effects  of  others.  This  was  performed  using  the  STATA
package (version 8.2; Stata Corp., College Station, TX).
RESULTS
Volunteers enrolled in this study were on the basis of the
following data: age, 16–25 years (mean, 18±3.3 years); male-
to-female ratio, 1.48:1.0; mean axial length (AXL), 24.8 mm;
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1775and mean spherical equivalent (SE), –4.5D. There were no
significant difference between the control and cases groups
with respect to age, gender, cornea diopter (CD), anterior
chamber depth (ACD), and LT (lens thickness; Table 1). The
study group comprised of 194 patients with high myopia, and
the control group consisted of 109 individuals with normal
eyes.  Four  polymorphisms  selected  for  this  study  are  as
described in Table 2: S1 (CHRM1 rs11823728), S2 (CHRM1
rs544978),  S3  (CHRM1  rs2186410),  and  S4  (CHRM1
rs542269).  The  genotype  distributions  of  the  CHRM1
polymorphism for both the high myopia group and controls
are shown in Table 2. There was significant difference in
genotype  and  allele  distribution  of  the  S2  (CHRM1
rs544978) polymorphism between high myopia patients and
normal controls (p=2.40×10-6 and 0.004, respectively) after
Bonferroni correction (Table 2 and Table 3). For S2 (CHRM1
rs544978), the genotype frequencies of G/G, A/G, and A/A
were 74.74%, 23.71%, and 1.55%, respectively, in the high
myopia  group  and  69.72%,  12.84%,  and  17.43%,
respectively,  in  the  control  group  (Table  3).  The  allelic
frequency of G and A was 86.60% and13.40%, respectively,
in  the  high  myopia  group  and  76.15%  and  23.85%,
respectively, in the control group (Table 2). There was also a
significant difference in the genotype distribution of the S4
(CHRM1  rs542269)  polymorphism  (p=2.38×10−8  after
Bonferroni correction) with the genotype frequencies of A/A,
A/G,  and  G/G  being  76.80%,  22.16%,  and  1.03%,
respectively, in the high myopia group and 83.49%, 2.75%,
and 13.76%, respectively, in the control group. The odds ratios
for an association with the S4 genotype were 8.75 (95% CI:
2.64–29.04) for A/G and 0.08 (95% CI: 0.02–0.36) for G/G.
However,  there  were  no  significant  differences  in  the
distribution of S4 alleles between the high myopia and control
groups (p=1.164 after Bonferroni correction; Table 2). The
frequencies of S4 alleles A and G were 87.89% and 12.11%,
respectively,  in  the  high  myopia  group  and  84.86%  and
15.14%, respectively, in the control group (Table 2). For S1
(CHRM1 rs11823728), the frequencies of genotypes G/G, A/
G, and A/A were 96.39%, 3.09%, and 0.52%, respectively, in
the  high  myopia  group  and  97.25%,  2.75%,  and  0%,
respectively, in the control group. The frequencies of the G
and A alleles were 97.94% and 2.06%, respectively, in the
high myopia group and 98.62% and 1.38%, respectively, in
the control group. There were no significant differences in the
genotype  and  allele  distributions  of  the  S1  (CHRM1
rs11823728) polymorphism between the high myopia and
control groups (p=2.96 and 2.176, respectively; Table 2 and
Table 3). There were also no significant differences in the
genotype  distributions  or  allele  frequencies  of  the  S3
polymorphism (CHRM1 rs2186410) between the two groups.
The p values of S3 (CHRM1 rs2186410) genotype and allele
were p=0.12 and 3.98, respectively (Table 2 and Table 3).
Moreover, we selected four haplotypes by phase software
v2.1.1 (Table 4). The haplotypes distributions of the Ht1 (G/
G/A/A), Ht2 (G/G/G/A), Ht3 (G/A/A/G), and Ht4 (C/A/A/A)
were also compared between the two groups. The haplotype
Ht4 (C/A/A/A) was significantly difference between the two
groups  (p=3.4×10−5,  OR:  0.1,  95%  CI:  0.03–0.34).  The
haplotypes frequencies of Ht1, Ht2, and Ht3 did not differ
significantly between the two groups (p=0.258, 0.6, and 1.56,
respectively; Table 4).
A logistic regression was used to determine the strength
of association of the four SNPs (Table 5) with high myopia.
Significant associations were found by the backward stepwise
procedure for all SNPs except S3 (p=0.9219). S2 had the
highest degree of association in the model (p=0.000) followed
by S4 (p=0.002) and then S1 (p=0.031) (Table 5). In the test
of HWE, there were departures from HWE for S1 in both the
control  and  high  myopia  groups  (p=0.048  and  0.023,
respectively) and for S2 in the control group (p=0.012). The
S3 and S4 polymorphisms were both in HWE.
DISCUSSION
Genetic studies have uncovered some polymorphisms, and
separate loci are correlated with high myopia including those
on chromosomes 18p and 12q [23,24] and on the genes of
myocilin [25], TGF (transforming growth factor) [26], PAX6
(paired box gene 6) [27], and COL1A1 (collagen, type I, alpha
1) [26]. This indicates that there is a genetic predisposition to
developing high myopia. However, no one gene can be solely
TABLE 1. CHARACTERISTICS OF THE STUDY SUBJECTS AND THE PARTIAL CORRELATION BETWEEN SPHERICAL EQUIVALENT AND OTHER OCULAR COMPONENTS.
Characteristics Control (SD) n=109 Cases (SD) n=194 All subjects (SD) n=303
Age, mean(SD), years 18 (2.8) 18 (3.5) 18 (3.3)
Female, n (%) 44 (40.4%) 78 (40.2%) 122 (40.3%)
SE, mean (SD), D 0.03 (0.31) −8.82 (2.4) −4.5 (2.1)
AXL, mean (SD), mm 23.8 (0.78) 26.8 (1.8) 24.8 (2.5)
CD, mean (SD), D 43.7 (0.8) 44.2 (1.8) 43.9 (1.2)
ACD, mean (SD), mm 3.57 (0.24) 3.89 (0.32) 3.62 (0.4)
LT, mean (SD), mm 3.8 (0.64) 4.0 (0.59) 3.9 (0.6)
SE: spherical equivalent (spherical equivalent equal to the sphere plus 1/2 the cylinder) spherical equivalent, AXL: axial length,
CD: cornea diopter, ACD: anterior chamber depth, LT: lens thickness.
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1776responsible  for  the  development  of  myopia,  especially
considering the wide variability in the prevalence of myopia
across different ethnic groups [27-31]. The mechanisms by
which  myopia  develops  are  further  obscured  by  the
uncertainty regarding the role of environmental factors. There
is a higher prevalence of myopia among individuals with
higher education levels than among members of the general
population.  Therefore,  medical  students  were  chosen  as
participants  in  the  present  study.  Because  both  the  high
myopia and control groups constituted medical students, we
believed  that  the  bias  associated  with  environmental
influences would be minimal.
TABLE 2. ASSOCIATION BETWEEN GENOTYPE DISTRIBUTIONS OF CHRM1 POLYMORPHISMS AND INDIVIDUALS WITH HIGH MYOPIA.
Polymorphisms Individuals with
myopia > 6.0D (%)
Individuals with
myopia < 0.5D (%)
OR 95% CI* p value#/Cp-value##
rs11823728 (S1)
G/G 187 (96.3) 106 (97.2) 1 - 0.74/2.96
A/G 6 (3.1) 3 (2.8) 1.13 0.28–4.63
A/A 1 (0.5) 0 (0) -
rs544978 (S2)
G/G 145 (74.7) 76 (69.7) 1 - 5.99×10−7/2.40× 10−6
A/G 46 (23.7) 14 (12.8) 1.72 0.89–3.33
A/A 3 (1.5) 19 (17.4) 0.08 0.02–0.29
rs2186410 (S3)
A/A 150 (77.3) 89 (81.7) 1 - 0.03/0.12
A/G 24 (12.3) 4 (3.7) 3.56 1.2–10.59
G/G 20 (10.3) 16 (14.7) 0.74 0.37–1.51
rs542269 (S4)
A/A 149 (76.8) 91 (83.5) 1 - 5.96×10−9/2.38×10−8
A/G 43 (22.2) 3 (2.8) 8.75 2.64–29.04
G/G 2 (1.0) 15 (13.8) 0.08 0.02–0.36
Genotype frequencies were compared between individuals with myopia greater than 6.00 D and less than 0.5 D. The asterisk
indicates CI=confidence interval. #The χ2  test or Fisher's exact test was performed to obtain the p value. It was considered
statistically significant if p was less than 0.05.  ##Cp-value, p-value corrected by Bonferroni correction.
TABLE 3. ASSOCIATION BETWEEN ALLELIC FREQUENCIES OF CHRM1 POLYMORPHISMS AND INDIVIDUALS WITH HIGH MYOPIA.
Alleles Individuals with
myopia > 6.0D (%)
Individuals with
myopia < −0.5D (%)
OR 95% CI* p value#/Cp-value##
rs11823728
G 380 (97.9) 215 (98.6) 1 0.544/2.176
A 8 (2.0) 3 (1.4) 1.51 0.4–5.75
rs544978
G 336 (86.6) 166 (76.1) 1   0.001/0.004
A 52 (13.4) 52 (23.9) 0.49 0.32–0.76
rs2186410
A 324 (83.5) 182 (83.5) 1   0.995/3.98
G 64 (16.5) 36 (16.5) 1 0.64–1.56
rs542269
A 341 (87.9) 185 (84.9) 1   0.291/1.164
G 47 (12.1) 33 (15.1) 0.77 0.48–1.25
The frequencies of alleles were compared between individuals with myopia greater than 6.00 D and less than 0.5 D. The asterisk
indicates CI=confidence interval. #The χ2 test or Fisher's exact test was performed to obtain the p value. It was considered
statistically significant if p was less than 0.05. ##Cp-value, p value corrected by Bonferroni correction.
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1777Clinical trials in school-aged patients have shown the
effectiveness of daily atropine administration, which reduces
the progression of myopia by approximately 60% at least in
the first year of treatment [27,28]. The effect of atropine was
suspected by depression of neuronal activity and leads to an
increase in the general release of retinal neurotransmitters
[22].  Furthermore,  there  is  evidence  that  pirenzepine  and
himbacine  inhibit  myopia  in  a  dose-dependent  fashion,
suggesting that these drugs mediate their effects through a
receptoral  mechanism  [13,14].  Different  muscarinic
antagonists  have  been  investigated  for  their  individual
effectiveness in reducing myopia. The efficacy of atropine,
pirenzepine (M1 selective antagonist), himbacine (M4/M2
selective  antagonist),  and  the  nonselective  muscarinic
antagonist, oxyphenonium, were all effective in the inhibition
of myopic eye growth [8,9,13,14], but individual mechanisms
were still unknown. Since the results of an in vitro study
suggest that the Ml mAChR subtype is most likely involved
in regulating scleral growth [16], we selected it as the target
gene in this study.
With  stepwise  logistic  regression,  we  found  an
association between three of the mAChR polymorphisms (S1:
CHRM1 rs11823728, S2:CHRM1 rs544978, and S4: CHRM1
rs542269) and high myopia. No association was found for S3
(rs2186410).  The  mAChR  polymorphism  most  strongly
associated  with  high  myopia  was  S2  (CHRM1  rs544978;
p=0.000) followed by S4 (CHRM1 rs542269; p=0.002) and
then S1 (CHRM1 rs11823728; p=0.031). This was compatible
with the genotype study. The frequencies of the AA genotype
of S2 and the GG genotype of S4 were significantly less in the
control  group  than  in  the  study  group,  that  is,  they  had
protective effects of subjects suffering from high myopia (OR
for  both:  0.08;  95%  CI:  0.02–0.29  and  0.02–0.36,
respectively). Allele analysis revealed that the “A” allele of
S2 had a significant protective effect against the development
of high myopia (p=0.004; OR: 0.49; 95% CI: 0.32–0.76).
However, the distribution of the “G” allele of S4 was not
significantly different between the high myopia and control
groups.  These  data  indicate  that  the  “GG”  homologous
genotype  of  S4  protects  against  the  development  of  high
myopia, and this function did not establish when only one “G”
allele existed. Moreover, we observed that the frequencies of
the haplotype Ht4 (G/A/A/A) differed significantly between
the two groups (p=3.4×10−5). The Ht4 haplotype occurred
more often in the control group than in the high myopia group
(7.3% and 0.34%, respectively). The Ht4 haplotype might
play a role in preventing the development of high myopia (OR:
0.1, 95% CI: 0.03–0.34). In conclusion, S1, S2, and S4 co-
contributed to the genetic background of high myopia.
TABLE 4. ODDS RATIOS AND 95% CONFIDENCE INTERVALS FOR THE ASSOCIATION BETWEEN CHRM1 HAPLOTYPES AND MYOPIA.
Haplotype* rs11823728 rs544978 rs2186410 rs542269
Individuals with
myopia > 6.0D (%)
Individuals with
myopia < −0.5D (%)
p value**,#/
Cp-value##
Odds Ratio 
(95% CI***)
Ht1 G G A A 272 138 0.086/0.258 1.36 (0.96–1.93)
Ht2 G G G A 61 26 0.2/0.6 1.38 (0.84–2.25)
Ht3 G A A G 38 25 0.52/1.56 0.84 (0.49–1.43)
The asterisk indicates the order of polymorphisms comprising CHRM1  haplotypes: rs11823728, rs544978, rs2186410, and
rs542269. The haplotypes were identified by the Bayesian statistical method available in the program, Phase 2.1. The double
asterisk means the χ2 test (2×2 table) was performed to obtain the p value. The number of haplotypes in eyes with myopia greater
than or equal to 6.0 D and less than or equal to 0.5 D with Ht1 was compared with the number of haplotypes in eyes with myopia
greater than or equal to 6.0 D and less than or equal to 0.5 D without Ht1. A p value of less than 0.05 was considered statistically
significant. Percentages may not add up to 100% because of the presence of rare haplotypes (below 0.3%) not presented in this
table.  #The χ2 test or Fisher's exact test was performed to obtain the p-value. The percentages of people with and without HT1
were compared between myopia and control groups. It was considered statistically significant if p was less than 0.05. ##Cp-
value, p-value corrected by Bonferroni correction. The triple asterisk indicates CI=confidence interval.
TABLE 5. THE MAIN EFFECTS OF SNPS BY STEPWISE LOGISTIC REGRESSION PROCEDURE.
Null model Alternative model p value
S1+S2+S3+S4 S1+S2+S4 0.9219
S1+S2+S3+S4 S2+S3+S4 0.031
S1+S2+S3+S4 S1+S3+S4 0.000
S1+S2+S3+S4 S1+S2+S3 0.002
Four polymorphisms were selected in this study and we defined them as S1: CHRM1   rs11823728, S2: CHRM1   rs544978, S3:
CHRM1   rs2186410, S4: CHRM1 rs542269.
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1778Our  study  design  has  strengths  and  limitations.  We
screened a large number of study subjects, and our study
population was relatively homogenous in terms of ethnicity,
geographic location, and age. The limitation was that the
target polymorphisms detected in this study were in the 3′UTR
and in the intron. These polymorphisms might contribute to
the physiologic function insignificantly. 3′UTR may alter the
RNA stability and/or its translational efficiency, and the intron
may alter mRNA splicing. All these implications should be
confirmed  by  experimental  data.  We  minimized  errors  in
genotyping  and  validated  our  findings  by  repeating  the
genotyping analysis several times and obtaining consistent
results. Therefore, occurrence of genotyping errors in this
study was kept to a minimum. In the HWE test, however, two
of the SNPs considered in our study were not in HWE. The
deviations from HWE might be a sign of mutation and may
increase  possible  association  with  myopia.  This
disequilibrium became other evidence of the association of
the polymorphisms in CHRM1 with high myopia. Moreover,
we tried to trace the ancestry background of controls and
patients. Eighty-five percent are of Minnan descendants, 5%
of them are Hakka descendants, and the remaining 10% are a
mixed population of Minnan, Hakka, and Canton descendants.
According to the paper published by Pan et al. [32], they
mentioned  that  the  SNP  profiles  in  the  major
histocompatibility complex (MHC) region (6p21.3) showed
no significant difference among Minnan descendants, Hakka
descendants  and  mixed  population  of  Minnan  and  Hakka
descendants,  which  indicate  the  homogeneity  of  the
population. Thus population stratification should not produce
in this study [32].
In the future, further studies are needed to confirm a role
of CHRM1 in high myopia. Indeed, we intend to replicate the
present study in a separate population group such as a non-
student sample. We also plan to analyze the genotypes of the
parents of the highly myopic participants of the current study
to minimize bias. Further, we intend to analyze data across the
spectrum  of  refractive  error  as  obtained  from  all  3,000
participants screened to further understand the relationship
between  CHRM1  and  the  severity  of  myopia.  Complex
diseases such as diabetes, cancer, asthma, and arthritis are
probably  caused  by  subtle  changes  in  multiple  genes
combined with environmental and lifestyle factors. Myopia is
considered  a  complex  and  multigenic  disease  involving
several overlapping signaling pathways, each mediated by a
group of distinct genetic profiles. Therefore, studying genetic
polymorphisms that are related to the mechanisms of myopia
can help to further clarify the relationship between genetics
and myopia. The discovery of associations between myopia
and  various  genetic  markers  has  helped  increase  the
knowledge  needed  for  the  prevention  and  treatment  of
myopia.  As  with  CHRM1,  CHRM4  encodes  a  receptor
important in the progression of myopia and also needs to be
investigated.
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